Complete Freund's Adjuvant Eyelid Disease Model

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

There is a lack of a suitable model animal and method for evaluating the therapeutic or prophylactic effects of drugs against eyelid diseases such as blepharitis and meibomian gland dysfunction, as no previous method has considered the influence of administering complete Freund's adjuvant on mammalian eyelids.

Innovation Solution

Administering complete Freund's adjuvant to mammals, such as rats or rabbits, to induce conditions like plugging of meibomian gland orifices and telangiectasia, which can be used to evaluate the therapeutic or prophylactic effects of test substances, thereby creating a model animal and screening method for eyelid diseases.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If complete Freund's adjuvant is administered to create an eyelid disease model, then the model reliability for evaluating therapeutic effects is improved, but the complexity of the administration method increases

Engineering Contradiction:
Improvemodel reliabilityVSAvoidmethod complexity
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The patent applies preliminary action by pre-administering complete Freund's adjuvant to mammals before testing therapeutic substances. This creates the eyelid disease model (plugging of meibomian gland orifices and/or telangiectasia) in advance, establishing a reliable baseline condition for subsequent evaluation of therapeutic or prophylactic effects of test substances.

Inventive Principle:
Principle #10Preliminary action

2Measurement precision

If complete Freund's adjuvant is administered to induce plugging and telangiectasia, then the measurement precision of therapeutic effects is improved, but the time required for model creation increases

Engineering Contradiction:
Improveevaluation precisionVSAvoidmodel creation time
Core Design Contradiction:
Measurement precisionVSLoss of time

Solution Approach 1:

The patent performs the model-creating action in advance by administering complete Freund's adjuvant before conducting therapeutic effect evaluations. This preliminary creation of the eyelid disease model (with plugging of meibomian gland orifices and/or telangiectasia) allows for precise measurement of therapeutic effects without time pressure during the actual evaluation phase.

Inventive Principle:
Principle #10Preliminary action

3Productivity

If complete Freund's adjuvant is administered to create a disease model, then the productivity of drug screening is improved, but the quantity of substances required for evaluation increases

Engineering Contradiction:
Improvescreening efficiencyVSAvoidtest substance quantity
Core Design Contradiction:
ProductivityVSQuantity of substance

Solution Approach 1:

The patent applies preliminary action by creating the eyelid disease model (through complete Freund's adjuvant administration-induced plugging and telangiectasia) before conducting the screening. This allows multiple test substances to be evaluated on already-established models, improving screening productivity without requiring excessive amounts of test substances, as the model creation is a one-time preliminary step.

Inventive Principle:
Principle #10Preliminary action

Data Source

PatentUS10143761B2Method for changing condition of an eyelid for evaluation of an eyelid disease involving plugging of meibomian gland orifices and/or telangiectasia by administration of complete freund's adjuvant
Publication Date: 2018.12.04 SANTEN PHARMACEUTICAL CO LTD

AI summary

A method for changing a condition of an eyelid of a mammal excluding a human, a model animal for evaluating a therapeutic or prophylactic effect against an eyelid disease obtained by the method, a method for producing the model animal, a method of screening using the model animal and a substance having a therapeutic or prophylactic effect against an eyelid disease selected by the method of screening, and a therapeutic or prophylactic agent against an eyelid disease containing the substance as an active ingredient.